pembrolizumab

• 

Pembrolizumab plus lenvatinib for non-clear cell kidney cancer

By Sharon Deveson Kell|2023-10-02T08:53:12+00:002 Oct 2023|Drug treatments|

Immunotherapy combinations are becoming the standard treatment for people with [...]

Read More

Comments Off on Pembrolizumab plus lenvatinib for non-clear cell kidney cancer

• 

Pembrolizumab plus lenvatinib as first-line treatment for advanced non-clear cell kidney cancer

By Sharon Deveson Kell|2023-07-18T06:58:37+00:0018 Jul 2023|Drug treatments|

Immunotherapy combinations are becoming the standard treatment after surgery for [...]

Read More

Comments Off on Pembrolizumab plus lenvatinib as first-line treatment for advanced non-clear cell kidney cancer

• 

Adjuvant therapy for kidney cancer

By Sharon Deveson Kell|2023-06-23T07:53:54+00:0023 Jun 2023|Drug treatments|

Adjuvant therapy aims to reduce the risk of the cancer [...]

Read More

Comments Off on Adjuvant therapy for kidney cancer

• 

Four-year follow-up with lenvatinib plus pembrolizumab for advanced kidney cancer

By Sharon Deveson Kell|2023-06-12T08:21:24+00:007 Jun 2023|Drug treatments|

Further follow-up data from the phase 3 CLEAR study with [...]

Read More

Comments Off on Four-year follow-up with lenvatinib plus pembrolizumab for advanced kidney cancer

• 

Benefits persist for lenvatinib plus pembrolizumab in advanced kidney cancer

By Sharon Deveson Kell|2023-03-15T09:03:59+00:0015 Mar 2023|Drug treatments|

Lenvatinib plus pembrolizumab has already been shown to improve survival [...]

Read More

Comments Off on Benefits persist for lenvatinib plus pembrolizumab in advanced kidney cancer

• 

ASCO GU 2023: Adjuvant pembrolizumab for different risks and stages of kidney cancer

By Sharon Deveson Kell|2023-02-22T09:34:55+00:0022 Feb 2023|Drug treatments|

At the American Society of Clinical Oncology Genitourinary Cancers Symposium [...]

Read More

Comments Off on ASCO GU 2023: Adjuvant pembrolizumab for different risks and stages of kidney cancer

• 

ASCO GU 2023: Patient perception of benefits and risks of adjuvant therapy for kidney cancer

By Sharon Deveson Kell|2023-02-22T09:52:33+00:0022 Feb 2023|Drug treatments|

At the American Society of Clinical Oncology Genitourinary Cancers Symposium [...]

Read More

Comments Off on ASCO GU 2023: Patient perception of benefits and risks of adjuvant therapy for kidney cancer

• 

Pembrolizumab plus axitinib for metastatic papillary and chromophobe kidney cancer

By Sharon Deveson Kell|2023-01-24T09:57:36+00:0024 Jan 2023|Drug treatments|

Non-clear cell kidney cancer is a group of different subtypes [...]

Read More

Comments Off on Pembrolizumab plus axitinib for metastatic papillary and chromophobe kidney cancer

• 

NICE approves pembrolizumab plus lenvatinib combination for advanced kidney cancer

By Sharon Deveson Kell|2022-11-30T15:29:22+00:0030 Nov 2022|Drug treatments|

The National Institute for Health and Care Excellence (NICE) has [...]

Read More

Comments Off on NICE approves pembrolizumab plus lenvatinib combination for advanced kidney cancer

• 

Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times

By Sharon Deveson Kell|2022-10-27T08:20:36+00:0027 Oct 2022|Drug treatments|

When ipilimumab plus nivolumab or axitinib plus pembrolizumab are used [...]

Read More

Comments Off on Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times